BCAB
Bioatla, Inc.
A San Diego biopharmaceutical company developing antibody-based medicines for solid-tumor cancers. Its signature Conditionally Active Biologics (CAB) platform engineers antibodies to stay switched off in healthy tissue and only wake up in the acidic environment of a tumor, sparing healthy cells. Founded in 2007 by biotech veteran Jay Short and Carolyn Anderson, the firm's name plays on that same idea—antibodies that act only under certain conditions.
CUSIP: 09077B104HealthcareUS1 holder
Total Value
$868.5K
Total Shares
634.0K
Net Share Change
+634.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
